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γ-aminobutyric acid receptors (GABAARs) are vital for controlling excitability 
in the brain. This is emphasized by the numerous neuropsychiatric disorders 
that result following receptor dysfunction. A critical component of most native 
GABAARs is the α subunit. Its transmembrane domain is the target for many 
modulators, including endogenous brain neurosteroids that impact on anxiety, 
stress and depression, and for therapeutic drugs such as general 
anaesthetics. To understand the basis for modulating GABAAR function, high- 
resolution structures are required. Here we present the first atomic structures 
of a GABAAR chimera at 2.8Å resolution, including those bound with 
potentiating and inhibitory neurosteroids. These define new allosteric binding 
sites for these modulators that are associated with the α-subunit 
transmembrane domain. Our findings will enable neurosteroids to be exploited 
for therapeutic drug design to regulate GABAARs in neurological disorders.      
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The GABAAR is a pre-eminent member of the pentameric ligand-gated ion channel 
(pLGIC) superfamily comprising amongst others, nicotinic acetylcholine (nAChR), 
glycine (GlyR) and serotonin type-3 (5-HT3R) receptors1, 2. GABAARs possess an 
anion-selective ion channel that, following agonist activation, enables Cl- flux to 
shunt and often hyperpolarise the membrane. This reveals their primary task in the 
brain, which is to inhibit neuronal excitation3 and it is widely acknowledged that 
dysfunctional GABA signalling results in neurological disorders4, 5.  
GABA signalling via type A receptors occurs by a combination of rapid phasic and 
persistent tonic inhibition. The former requires the activation of synaptic GABAA 
receptors composed of αβγ subunits that are clustered at inhibitory synapses. The 
latter involves diffusely-located extrasynaptic αβγ and αβδ subunit-containing 
GABAARs3, 6. Whilst varying the receptor subunit composition confers distinctive 
physiological and pharmacological properties7, all GABAARs share core fundamental 
properties. Both synaptic and extrasynaptic receptor classes desensitize8-10 upon 
prolonged agonist exposure, and both are modulated by naturally-occurring brain 
neurosteroids11 that ‘fine-tune’ the time-course and extent of postsynaptic inhibition.   
An important and common structural denominator for most GABAARs is the α-
subunit. There are six isoforms (α1-6) and of these α1 is the most widely expressed 
in the brain12. In combination with β2/3 and γ2 subunits this forms the prototypic 
synaptic GABAAR. The extracellular domain (ECD) of the α-subunit is vital in forming 
part of the interfacial GABA binding sites between β-α subunits. Notably, structural 
elements within the α subunit transmembrane domain (TMD) shape GABA channel 
architecture and also strongly influence the biophysical and pharmacological 
properties of individual GABAAR subtypes7, 13, including their modulation by 
neurosteroids14 and general anaesthetics15. Naturally occurring neurosteroids are 
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synthesised in the brain from cholesterol and represent a potent endogenous 
modulator of GABAergic transmission. These compounds can modulate both 
synaptic and extrasynaptic receptors11 and are classified on their ability to potentiate 
or inhibit GABAAR activity. Significantly the GABAAR α-subunit TMD confers 
sensitivity to neurosteroids such as allopregnanolone and its derivatives14.   
To further our understanding of GABAAR function, and how this depends on 
modulation by allosteric ligands, requires the generation of new structural 
information. This will also provide insight into the disruptive effects of receptor 
mutations that are associated with neuropsychiatric diseases16. To date, structural 
studies have been limited mainly to a reliance on homology modelling and structural 
comparisons between homologous pLGIC members for which atomic level resolution 
is available2.   
Here, we describe structural details of the GABAAR at atomic resolution based on 
using a new chimera-based modular construct. We present crystal structures of the 
GABAAR α1-subunit transmembrane domain alone, and in complex with the two 
classes of brain neurosteroids: the potentiating stress hormone-derived tetrahydro-
deoxycorticosterone (THDOC), and the inhibitory neurosteroid, pregnenolone sulfate 
(PS). These new receptor structures also allow clear observation of the GABA ion 
channel for which we can resolve the recently defined desensitization gate that lies 
deep within the pore10.   
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RESULTS 
Designing a functional GABAA receptor chimera 
To provide high-resolution X-ray crystallographic structural information for the 
GABAAR TMD, we developed a new ‘prokaryotic-eukaryotic’ chimera. This involved 
fusing the ECD of the prokaryotic homolog GLIC from Gloeobacter violaceus17, 18, 
with the TMD (comprising the α-helices M1-M4 and associated linkers) from the 
GABAAR α1-subunit (Fig 1a, Supplementary Fig. 1a). GLIC was selected for 
constructing the chimera since it readily crystallises as a homomer17, 18, with principal 
crystal contacts contributed by the ECD. Moreover, it forms a functional chimera 
when fused to the TMD of a similar pLGIC, the GlyR19. Finally, the kinetic profiles of 
proton-activated currents for wild-type (WT) GLIC are slow and distinct from that for 
most GABAARs (Fig. 1b). This enables the functional and pharmacological 
characteristics of the chimeric GABAAR α1-subunit TMD to be readily identified.  
Previous studies of pLGICs have revealed that the interfacial loops at the base of the 
ECD, and the extracellular segments of the TMD, are important for transmitting the 
process of agonist-binding to ion channel opening1. In the chimera, loops 2, 7 and 9 
at the base of the ECD β-sheets, which are important for transmitting the agonist 
binding signal1, are contributed by GLIC, while the M2-M3 linker of the TMD derives 
from the GABAAR α1-subunit (Supplementary Fig. 1a). In optimising the chimera for 
crystallization, the large intracellular M3-M4 domain was replaced with the shorter 
linker from GLIC, -SQPARAA- (Fig. 1a, Supplementary Fig. 1a).  
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Functional properties of the GABAA receptor chimera 
To ensure that the GLIC-GABAARα1 chimera was functional, receptors were 
expressed in Xenopus oocytes and assessed using two-electrode voltage clamp 
(TEVC) electrophysiology. As predicted for a chimera incorporating the ECD from 
GLIC and the TMD from the GABAAR α1-subunit, it was activated by protons in a 
concentration-dependent manner, yet formed a Cl- selective ion channel 
characteristic of GABAA receptors (Supplementary Fig. 1b-d). Accordingly, proton-
activated currents were inhibited by the GABA channel blocker picrotoxin (Fig. 1c,d). 
Furthermore, prolonged proton applications evoked desensitizing Cl- currents, similar 
to response profiles for α1β3 GABAARs activated by high GABA concentrations, and 
therefore distinct from the slower response of WT GLIC channels (Fig. 1b). Protons 
can modulate native GABAARs, but this is critically dependent on a histidine residue 
in the TMD of the β-subunit 20. This is absent in our chimera and therefore suggests 
that residues in the ECD determine the sensitivity to protons. 
To further validate the chimera as a new model for α1 subunit-containing GABAARs 
we mutated key residues within the TMD that underpin gating transitions that affect 
receptor desensitization (Supplementary Fig. 1e). Consistent with results from α1β2 
GABAARs10, mutating valine 251 at -3’ in M2 (numbered from a conserved arginine 
at the base of M2 defined as position 0’) to isoleucine (V251I), or by mutating glycine 
258 (4’) to valine or alanine (G258V, A), yielded chimeras exhibiting profound 
desensitization following proton activation (Fig. 1e). Thus, the characteristics of the 
chimera TMD are in accord with those expected of the GABA α1-subunit TMD.    
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Crystal structure of the GABAA receptor chimera 
After screening for the expression and purification of various receptor chimeras in 
Sf9 insect cells, we noted that purification of GLIC-GABAARα1 was markedly 
improved by including the desensitizing G258V mutation (Supplementary Fig. 2a,b). 
Significantly, this receptor (GLIC-GABAARα1G258Vcryst) retained its functionality (Fig. 
1b) and was thermostable as a pentamer in detergent micelles (Supplementary Fig. 
2c,d).  
We determined the crystal structure of GLIC-GABAARα1G258Vcryst at 2.8Å resolution 
under low pH, to capture the receptor in an agonist-bound, desensitized 
conformation (Supplementary Fig. 3, Table 1). The chimera forms a homo-pentamer 
with each subunit composed of an ECD, comprising inner and outer layers of β-
sheets from GLIC, coupled to four α-helices in the TMD with an integral pore from 
the α1-subunit (Fig. 2). A continuous solvent accessible pathway (characteristic of all 
pLGICs) follows a 5-fold symmetry axis through the centre of the ECD and TMD. A 
positive electrostatic surface potential extending the length of the TMD is conducive 
to Cl- permeation (Supplementary Fig. 4). The ECD structure is compact21, 22, with 
bound acetate ions contributed by the crystallisation solution, consistent with the 
agonist-bound state for WT GLIC23, 24.  
The ECD (Supplementary note 1) is connected to the GABA α1-subunit TMD 
through extensive interactions between ECD loops 2, 7 and 9 and the M2-M3 linker 
of the TMD (Fig. 3). Crucially, by adopting a cis conformation, the conserved proline 
(P120) at the tip of loop 723 enables hydrogen (H)-bonding between the backbone-
carbonyl of Y119 and residues at the tip of M3. The hydroxyl group of Y281 
(equivalent to Y251 in GLIC) in the M2-M3 linker also forms an H-bond with the 
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backbone amino-group of F115 on loop 7. This interaction further stabilizes domain 
coupling (Fig 3b). The conserved nature of these ECD-TMD interactions ensures ion 
channel gating follows agonist binding. It also highlights the critical role of the highly 
conserved K278 in the M2-M3 linker25 (Fig 3b,c), which is also conserved in GLIC 
(K248). Previous studies of α1β2γ2 GABAARs reveal a role for this residue in the 
initiation of channel gating26, where it likely stabilises an open state of the 
GABAAR27. Furthermore, disrupting these interactions by mutating in α1-subunits, 
causes familial epilepsies28. 
The geometry of the GABAAR α1-subunit pore (Fig. 4) exhibits structural similarities 
with other pLGICs under non-resting conditions. These include: GLIC at acidic pH in 
an ‘agonist-bound’ state17, 18; glutamate-activated Cl- channels (GluClcryst) bound to 
ivermectin29; GABA β3 homomers bound with benzamidine30; and ligand-bound 
GlyRα131 and GlyRα332.  The channel lining M2 α-helices reveal an expanded pore 
at the extracellular portal (at 20’; Fig. 4a,b) that gradually tapers towards the 
intracellular exit at -2’, which is characteristic of a desensitized conformation (Fig. 
4b,c). This structure is distinct from that for GLIC-GlyRα1, which adopts a locally-
closed conformation when crystallized at low pH19 (Supplementary Fig. 5). In 
addition to M2, both the M1 and M3 α-helices of the GLIC-GABAARα1 chimera also 
superimposed onto related pLGIC TMD structures. However, the extracellular end of 
M4 was rotated around a highly conserved proline (P400), compared to M4 in GABA 
β3 homomers (Fig 4a). 
At the extracellular end, the expanded pore is stabilized by an intra-subunit salt 
bridge between R273 (19’ in M2) and D286 (in M3), and by inter-subunit H-bonding 
between N274 (20’ in M2) and Q228 (in M1, which is also highly conserved across 
most GABAAR subunits; Fig 3c). Notably, although two cysteines on M1 (C233) and 
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M3 (C292) are in close proximity, they do not form a disulfide bridge (as proposed 
from homology modelling studies33). Looking deeper into the pore, the leucine ring at 
9’ associated with the activation gate34 is open (pore radius ~5Å) with side-chains 
rotated out towards M2 of the adjacent subunit. This is also observed for structures 
of the GABA receptor β3 homomer, GlyRα1, and GlyRα3 bound to ivermectin (Fig 
4b, Supplementary Fig. 5)30, 31, 35.  
Descending further into the pore, two constrictions are evident formed by rings of 
residues at 2’ (Val) and -2’ (Pro; Fig. 4d,e, Supplementary Fig. 5). This region forms 
the ‘desensitization gate’ recently described for GABAARs and GlyRs10, and the ion 
selectivity filter23. The pore is narrowest at the -2’ proline (2.1 Å radius) allowing the 
passage of Cl- lacking a hydration shell (1.8 Å radius), whilst precluding hydrated Cl- 
(~3.3 Å radius; Fig. 4b-d, Supplementary Fig. 5). Analysing the surface potential 
electrostatics of the channel reveals an electropositive region at the intracellular end 
(Fig. 4f, Supplementary Fig. 4), which would facilitate anion-selective permeation. 
This potential likely arises from side-chain dipoles in M2 α-helices29. Given that the 
chimera channel is anion-selective, peaks in electron density maps in the pore can 
be tentatively assigned to Cl- ions (~6σ in Fo-Fc maps). This location is in spatial 
proximity to the anion-binding sites proposed for anion-selective GluCl29 and GlyRα3 
channels36. Moreover, a self-stabilized arrangement of water molecules, similar to 
those in GLIC23, is apparent at the level of 6’ Thr (Supplementary Fig. 4). 
Interestingly, at the cytosolic face, the chimera TMD exhibits ‘pockets’ of positive 
electrostatic potential, reminiscent of those in anion-selective GluCl channels 29 
(Supplementary Fig. 4).  
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Previous patch-clamp studies of GLIC at pH < 4.5, revealed that entry into a 
desensitized state occurs within ~1.5 - 10 s37, 38. Here, introducing G258V near to the 
physically-constricted desensitization gate between 2’ and -2’ of GLIC-GABAARα1 
resulted in currents that rapidly declined (Fig. 1b,e), suggesting that GLIC-
GABAARα1G258Vcryst adopts a desensitized conformation at pH 4.5. Indeed, residues 
known to affect GABAAR desensitization10 similarly affected proton-activated 
responses for the chimera (Fig. 1e), and formed steric interactions at the interface 
between M2 and M3, near the base of the TMD (Fig. 4e). Our structure reveals that 
this putative desensitized state is stabilized by intra-subunit salt bridges between 
R254 (0’ in M2) and E302 (M3) and D392 (M4) at the base of the helical bundle, and 
by inter-subunit H-bonding between N307 (M3) and the backbone amino group of 
N247 (in the M1-M2 loop; Fig. 3d). This provides structural evidence for a pLGIC in a 
desensitized state.  
 
Cholesterol binding to the GABAA receptor chimera 
A common structural feature of the proton-bound chimera was electron density (~5σ 
in Fo-Fc maps) at a cavity between M3 in the principal (p, +) subunit and M1 from the 
complementary (c, -) subunit (Supplementary Fig. 6a,b). This was assigned to 
cholesteryl hemisuccinate (CHS) used during purification. The site partially overlaps 
with sites for lipids and ivermectin in GluCl29, 39 and for ivermectin in GlyRs31, 35 
(Supplementary Fig. 6). Modelling and refinement of CHS indicated that its 
orientation best fit the electron density when cholesterol was tilted away from the 
receptor with the hemisuccinate moiety protruding between M3 and M1. This group 
could H-bond with S269 (15’ in M2), which is a key determinant for allosteric 
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modulation of GABAARs by volatile anaesthetics, and of GLIC by ethanol22, 40, 41 
(Supplementary Fig. 6). This location for CHS is analogous to that proposed for 
cholesterol at GABAARs from homology modelling and molecular dynamic (MD) 
simulations33. This suggests that without the bulky hemisuccinate group, cholesterol 
could penetrate deeper into this interface, forming an H-bond between the hydroxyl 
group of the cyclohexanol ring and 15’ serine33.  
 
Location of the potentiating neurosteroid binding site 
GABAARs are major targets in the brain for naturally-occurring neurosteroids derived 
from stress (e.g., tetrahydro-deoxycorticosterone (THDOC: Fig. 5a)) or sex (e.g., 
allopregnanolone) hormones11. These molecules potentiate GABAAR function at 
physiologically-relevant nanomolar concentrations, while at higher (micromolar) 
concentrations they cause direct receptor activation. Given their high potency at 
GABAARs, the potential for therapeutic application of neurosteroids is particularly 
appealing42. A highly conserved binding site underlying the neurosteroid potentiating 
action is considered, from homology modelling and mutagenesis, to be located within 
the α-helices of GABAAR α subunits14.  
To identify the neurosteroid binding site, we used the GLIC-GABAARα1G258Vcryst 
chimera, which is sensitive to THDOC, evident from the markedly potentiated proton-
activated currents using TEVC and increased thermal stabilisation of the detergent-
solubilized receptor (Fig. 5b,c, Supplementary Fig. 2e). Moreover, as for native 
GABAARs, THDOC could also directly activate the chimera in the absence of 
protons. These effects of THDOC are comparable to those observed with native 
GABAARs (α1β3 EC50s for potentiation and direct activation: 0.57 ± 0.1 μM; 2.46 ± 
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0.02 μM (n = 4 and 3 independent experiments) respectively; Fig. 5c). We observed 
no sensitivity to 1 – 3 μM THDOC for GABA β3 homomers (EC10 pentobarbitone-
gated current 99.3 ± 2.0 % of control, n = 3) or WT GLIC receptors (EC20 proton-
activated current 93.9 ± 1.7 %, n = 7).  
To explore the basis for neurosteroid binding to GABAARs, we determined the 
structure of GLIC-GABAARα1G258Vcryst bound to THDOC at 3.8 Å following co-
crystallization. Neurosteroid molecules were bound to each subunit TMD. These 
were not located within the α1-subunit α-helices, as previously proposed14, but 
unambiguously across the subunit-subunit interface (Fig. 5d, Supplementary Fig. 
7a,b). The electron density maps allowed confident positioning of the β-face of the 
neurosteroid backbone and orientation of the critical A-ring hydroxyl group at position 
C3.  
At this new site, the ring core of THDOC binds in a ‘hydrophobic groove’ that runs 
between juxtaposed subunits, anchored by H-bonding at each end of the molecule. 
This conforms to a canonical steroid binding site (Fig. 5e,f, Supplementary Fig. 7). 
The architecture of this site and the strong electron density for bound THDOC 
confirmed the pivotal binding role previously assigned to Q241 in M1 of the α1 
subunit14. A single H-bond is formed between Q241 in the complementary (c, -) 
subunit and the C3α hydroxyl in ring A of THDOC (Fig. 5e,f). The importance of 
Q241 was demonstrated by its mutation (Q241L), which ablated neurosteroid 
sensitivity (Fig. 5g) without affecting the proton sensitivity of the chimera 
(Supplementary Fig. 1d). The complementary subunit also contributes a tryptophan 
(W245) to the neurosteroid binding site, which is critical for neurosteroid potentiation 
at recombinant GABAARs43. The indole side-chain of W245 is orientated parallel to 
THDOC rings C and D, presumably interacting via hydrophobic stacking (Fig. 5e,f). 
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As predicted, its mutation (W245L) ablated neurosteroid potentiation (Fig. 5g). The 
orientation of the neurosteroid is supported by serial mutations of Q241 revealing 
that potentiation is maintained if the substituent is an H-bond acceptor (e.g., Q, N 
and H) but not if it only engages as an H-bond donor (e.g., W, R and K)14. Given that 
the C20 ketone of THDOC can only act as an H-bond acceptor, this argues for a 
molecular orientation in the binding site whereby the C3α hydroxyl of THDOC H-
bonds to Q241. 
Across the subunit interface, THDOC’s ring D ketone forms another H-bond with 
T305 in M3 of the principal (p, +) subunit (Fig. 5e,f), and, consistent with a binding 
role for this residue, its substitution by tryptophan (T305W) ablated THDOC 
potentiation (Fig. 5g). The corresponding residue in the β-α interface of native β3-
containing GABAARs is F301. Interestingly, this is photolabelled by a neurosteroid-
analogue in GABA β3 homomers, in accord with a binding role44. The base of the 
binding pocket in the principal subunit is formed by the aromatic ring of Y308, a 
residue highly conserved across GABAARs subunits. In the physiological context of 
binding at the β-α interface of GABAARs, it is apparent that the steroid molecule is 
also physically supported by aromatic residues contributed by both subunits. Whilst 
there is strong conservation of these aromatic residues across inhibitory pLGICs 
(Supplementary Fig. 1e & 7), modulation by THDOC is primarily dependent upon H-
bonding at the complimentary face to Q241 in M1. This is only provided by the α-
subunit containing receptors and not present in β subunits (Supplementary Fig. 7e). 
We performed MD simulations to corroborate our crystallographic interpretation for 
the orientation of THDOC in the binding site. Of many potential docking poses, only 
one consistently mapped onto the crystal structure. In this position Q241 and W245 
would coordinate with the A-ring of THDOC, while T305 coordinates the D-ring 
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(Supplementary Fig. 8a,b & Supplementary Movie 1). The THDOC position remained 
stable during MD simulation. Notably, the C3α hydroxyl group donated an H-bond to 
Q241, and the C21 hydroxyl of THDOC was orientated towards the membrane 
where it could donate an H-bond to the lipid head groups. 
Interestingly, the effects of THDOC on receptor structure are subtle. Although such 
small movements are insufficient to provide extensive insight, it is apparent that the 
overall structural geometry conforms to that observed for the proton-bound chimera 
structure in a desensitized state. The THDOC-bound structure thus resembles that of 
GlyRα1 bound to ivermectin31 and GlyRα3 bound to the analgesic, AM-360736,  
which both potentiate the agonist response. Considering the physical contours and 
binding interactions of the neurosteroid binding site described here, and from 
previous electrophysiological studies14, we would expect this site to accommodate 
potentiating neurosteroids of distinct stereochemistry exhibiting high efficacy 
modulation of GABAARs45, 46.   
 
Inhibitory neurosteroid binding site involves M3 and M4 
GABAARs are also modulated by naturally-occurring inhibitory neurosteroids in the 
brain, exemplified by pregnenolone sulfate (PS; Fig. 6a). Their binding site on 
GABAARs has remained elusive although the consensus view is that PS binds at a 
discrete site from that for potentiating neurosteroids47. Expressing GLIC-
GABAARα1G258Vcryst in Xenopus oocytes and using TEVC indicated a PS binding site 
was present with an apparent affinity comparable to that for native GABAARs (Fig 
6b). To establish its location, we co-crystallized the chimera with PS (Supplementary 
note 2). Electron density maps for PS-bound crystals (at 3.0 Å) revealed distinctive 
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peaks of density along the bilayer exposed face of M3 and M4 (Fig. 6c, 
Supplementary Fig. 8c). Modelling of PS suggests it aligns perpendicularly to the 
membrane at this intra-subunit site possibly engaging in van der Waals interactions 
principally along the outer face of M4. Although we cannot precisely orientate PS at 
this resolution, MD simulations indicated that the ring A sulfate group points towards 
the base of the TMD, potentially interacting with K390 (side-chain density for which 
was missing in diffraction data; Fig. 6c, Supplementary Fig. 8c-e & Supplementary 
Movie 2). The PS ring structure most likely interacts with several residues including 
I391, A398 and F399 in pM4.  
PS poses from MD simulations were less stable compared to those for THDOC, 
possibly reflecting the labile nature of this site. From different starting orientations, 
PS had a tendency to transition rapidly into an alternative pose in its proposed 
binding site. In this position, the β-surface-protruding methyl groups are oriented 
towards the hydrophobic environment of the membrane, the sulfate group forms a 
salt bridge with K390, and the PS ring core interacts with subsequent turns of the M4 
α-helix up to L402.   
This discrete site and the varied nature of the residues involved, may explain the 
enigmatic nature of PS modulation, and account for the difficulties in identifying its 
binding site47. In accord with a discrete site, PS inhibition was unaffected by mutating 
Q241, W245 or T305, which ablated THDOC potentiation (Fig. 6d, Supplementary 
Fig. 8f)48. However, mutating charged (K390A) or hydrophobic (I391C, A398C and 
F399C) pM4 residues in the chimera significantly reduced the inhibition of steady-
state currents by PS (Fig. 6e). To investigate further, we developed a kinetic model 
(Supplementary Methods) to simulate the effects of PS and the M4 mutations. By 
assuming PS binds preferentially to the activated/desensitized states of GLIC-
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GABAAR147, the model suggested that the mutations caused small changes (3-4-
fold) promoting receptor entry into a desensitized state and increasing entry into 
agonist bound-blocked states. There was minimal effect on the PS dissociation 
constant and overall, the mutated residues had more profound effects on PS efficacy 
than potency, which may partly explain its mechanism of inhibition (Supplementary 
Fig. 8g). 
 
DISCUSSION 
Here we present a new GABAAR chimera that allows the structural and functional 
examination of the α1-subunit transmembrane domain for one of the brain’s most 
prevalent inhibitory neurotransmitter receptors. 
Our description of a novel crystal structure for a functional GLIC-GABAARα1 chimera 
has enabled the structural interrogation of the GABAAR α subunit TMD. This domain 
contains numerous modulator binding sites, including the GABA ion channel. We 
reveal several important facets. Firstly, a precise structural location for the binding 
site for the potentiating neurosteroids. The GABAAR subunit interface is evidently 
critical for modulation by potentiating neurosteroids. Previously, we had proposed 
that two sites were necessary to explain the direct activation of the receptor by 
neurosteroids and potentiation of receptor function. However, with the new structure 
presented here both activation and potentiation apparently proceed from a single 
interfacial binding site, a feature that is explicable by using a Monod-Wyman-
Changeux model of receptor operation49. Secondly, whereas potentiating 
neurosteroids discretely bind between subunits near the lipid interface, inhibitory 
neurosteroids seemingly bind to a discrete intra-subunit TMD site. 
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Thirdly, we definitively describe the desensitization gate for GABAARs, caused by 
constriction at the base of the ion channel. This structural feature is conserved 
across anion-permeable pLGICs captured in desensitized-like states (e.g. GABA 
receptor β3 and GlyRα1 bound to ivermectin). It is also notable in the recent crystal 
structure of a heteromeric α4β2 nAChR50 that a similar constriction of the ion 
channel is evident at the cytosolic portal, consistent with a non-conductive, 
desensitized state. This, together with the structure presented here, suggests 
common structural features underpin desensitization in both anion- and cation-
permeable pLGICs.  
Finally, it is clear that the α-subunit interface in GABAARs also forms a binding site 
for another important class of modulators, the intravenous general anaesthetics 
(e.g., etomidate), which can photolabel the β+-α- interface at a methionine (M235) in 
the α1-subunit51 (Fig. 7a). Our crystal structures reveal that the etomidate and 
neurosteroid binding sites are non-overlapping, such that the same interface can 
accommodate both molecule types binding simultaneously (Fig. 7a). This likely 
explains why neurosteroids will enhance potentiation by etomidate52. 
Further interrogation of the chimera structure at the subunit-subunit interface also 
revealed a lateral aqueous tunnel. This originates from the lipid bilayer and opens 
into the ion channel at 15’ level. This tunnel is part of a larger inter-subunit cavity 
lined by residues implicated in anaesthetic binding; it is also partly-occupied by CHS 
(Fig. 7b,c, Supplementary Fig. 6d).  
Given the significant role neurosteroids play in anxiety, stress and other neurological 
disorders11, these modular structures provide a new template for exploring how 
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allosteric sites can be used by drugs to modulate GABAARs - an area of significant 
physiological, pathological and future therapeutic relevance for the brain.    
Words 3995 
 
METHODS 
All details regarding the methods used can be found in the online version of the 
paper. 
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Figure Legends   
Figure 1 Structure and function of the GLIC-GABAAR1 chimera. 
(a) Schematic representation of the GLIC-GABAARα1 chimera. The ECD is 
contributed by the GLIC subunit (green, residues 1-194) and the TMD is from the 
GABAAR α1 subunit (blue, residues 223-428, excluding the intracellular domain 
between M3 and M4, which derives from GLIC, green loop). (b) Peak-scaled 
currents induced by applied (bar) orthosteric agonists for: α1β3 GABAAR (10 mM 
GABA); wild-type (WT) GLIC (protons - pH 4); and chimera constructs with and 
without the G258V mutation (proton – pH 4). GLIC-GABAAR1G258Vcryst was used for 
crystallization experiments. (c) The GABAA channel blocker picrotoxin (PTX; 1 mM) 
inhibits proton-activated currents (pH 4) in the chimera voltage-clamped at -60 mV. 
Dotted lines show the extent of steady-state current inhibition. (d) Bar-graph showing 
current remaining after PTX inhibition of peak and steady-state pH4 currents. Values 
are means ± sem (n = 4 for both, independent experiments). Note the peak currents 
are more profoundly inhibited by PTX compared to steady-state currents. (e) Peak-
scaled proton-activated (pH 4 – 4.5) currents (VH = -60 mV) for chimeras with gain-
of-desensitization mutations in the α1-subunit TMD 10. Increased residue side-chain 
volume at the -3’ Val and 2’ Gly in M2 increases the rate of desensitization.  
 
Figure 2 Structure of the GABAA receptor chimera. 
Crystal structure of the chimera showing side (a) and plan (b) views with the ECD 
from GLIC (green) and the TMD of GABAARα1 (blue). M2 helices (cyan) line the ion 
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channel. Cholesteryl hemisuccinate molecules (orange) and the detergent acyl 
chains (yellow) are bound at the periphery of the TMD and shown in stick form.  
 
Figure 3 Coupling at the receptor chimera ECD-TMD interface.  
(a) Side-view of the receptor showing two subunits forming the principal (p, +) and 
complementary (c, -) inter-subunit interfaces. The dashed boxes are magnified in 
panels b-d. (b) Residues that interact at the coupling interface between the ECD and 
TMD are shown. Identified residues (in stick form) are broadly conserved across 
GLIC and GABAA receptor subunits, and putative H-bonding is shown by black 
dashed lines. (c) Residues involved in putative inter-subunit H-bonding and intra-
subunit salt-bridge interactions in the upper half of the TMD are shown. The Cys 
residues (yellow) in M1 and M3 do not form a disulfide bridge. (d) Residues involved 
in putative inter-subunit H-bonding and intra-subunit salt-bridge interactions in the 
lower half of the TMD are shown.  
 
Figure 4 Structure of the GABAAR chimera channel in a desensitized state. 
(a) Plan view superimposing WT GLIC and GABA β3 subunit TMDs on GLIC-
GABAAR1G258Vcryst revealing conformational changes to the TMD principally by 
tilting of M2 and rotation of M4. (b) Two M2 α-helices of the GLIC-
GABAARα1G258Vcryst (blue) are shown with equivalent M2 helices from WT GLIC 
(green) and GABA β3 (red) subunits. Note the tilting of the helices to form a 
constriction in the lower part of the pore (box). The solvent accessible volume of the 
channel is represented by spheres. (c) Pore radius profiles through the channel. The 
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ordinate directly relates to (b) for GLIC-GABAARα1G258Vcryst, GABA β3 and WT GLIC 
open state channels. (d) Pore constrictions formed by M2 lining residues at the level 
of -2’ Pro, 2’ Val (desensitization gate) and 9’ Leu (activation gate; all shown as C-
spheres with distances in angstroms (Ǻ)). (e) Residues lining the M2-M3 interface 
and M1-M2 linker form the components of a desensitization gate. (f) Positive 
electrostatic surface potential of the chimera at the cytoplasmic portal of the ion 
channel. Cl- ions are represented as green spheres and omit style map is calculated 
when ions were excluded from the refinement (contoured at 2σ, orange). 
 
Figure 5 Interfacial subunit binding site for the neurosteroid THDOC. 
(a) Chemical structure of THDOC in 2D and 3D. (b) Membrane currents for GLIC-
GABAARα1G258Vcryst (expressed in Xenopus oocytes) activated by protons (EC10-15) in 
the absence and presence of THDOC revealing profound potentiation. (c) Proton 
and THDOC concentration-response curves for the chimera. Normalized plots 
represent fits to mean ± sem data points with the Hill equation for potentiation (blue) 
by THDOC of the pH6 (EC10) current (= 100 %), or direct activation (red) of the 
chimera by THDOC. EC50 value for potentiation is 1.23 ± 0.09 µM (n = 4), and for 
direct activation, 2.30 ± 0.09 µM (n = 3). (d) For GLIC-GABAARα1G258Vcryst, THDOC 
(green sticks) binds across each subunit-subunit interface (box) in the pentamer. 
(e,f) THDOC binding at interfaces between principal (p) and complementary (c) 
subunits. Side-views (in the membrane, e) and plan views (extracellular, f) are 
shown. Dashed lines indicate H-bonding (distances; Q241-steroid, 2.4 - 2.9 Å and 
T305-steroid, 3.1 - 3.4 Å). Putative hydrophobic interactions (<4 Å) are formed 
between W245 and rings C and D of THDOC. Labelled residues contribute directly to 
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neurosteroid binding or line the binding pocket. (g) Relative effects of Q241L, W245L 
and T305W mutations on THDOC (500 nM) potentiation of GLIC-GABAARα1G258Vcryst 
proton-activated responses. Data shown are means ± sem of biological replicates 
(Ctrl (G258V) n = 4 oocytes; +Q241L n = 3; +W245L n = 4; +T305W n = 6). Results 
are representative of injections into oocytes taken from 3 Xenopus laevis performed 
over 5 separate days. 
 
Figure 6 Inhibitory neurosteroid pregnenolone sulfate binds at a distinct site.  
(a) Chemical structure of pregnenolone sulfate (PS) in 2D and 3D. (b) Inhibition of 
submaximal (pH 5.5) membrane currents for GLIC-GABAARα1G258Vcryst by PS. (c) 
Intra-subunit binding site for PS (cyan sticks/spheres) located at the lipid face of M3 
and M4 α-helices, viewed from the plane of the membrane. Hydrophobic and 
aromatic residues that line the bilayer-exposed face of M3 and M4 are labelled. 
These form a smooth groove at the protein surface, with PS bound alongside the α-
helices. Residues that bind THDOC (forming the potentiating neurosteroid binding 
site) are labeled in green, and THDOC orientation is shown by the transparent green 
oval shape. Cholesteryl hemisuccinate binding is also indicated (orange sticks). (d) 
Relative effects of Q241L, W245L, and T305W mutations on PS (10 M) inhibition of 
GLIC-GABAARα1G258Vcryst proton–activated responses. Values are means ± sem (n = 
4, 4, 6 and 3, respectively from independent experiments). (e) Proton-activated 
(pH4.5) steady-state current inhibition by PS for GLIC-GABAARα1G258Vcryst, and for 
the chimeras containing either K390A or I391C, A398C, F399C mutations. The curve 
fits were generated by the inhibition model equation. Note the reduced inhibition for 
the mutant receptors. Data shown are means of biological replicates (Ctrl (G258V) n 
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= 4 oocytes; +Q241L n = 4; +W245L n = 4; +T305W n = 6; +K390A n = 4; + I391C, 
A398C, F399C n = 4). Results are representative of injections into oocytes taken 
from 8 Xenopus laevis performed over 18 separate days. 
 
Figure 7 Inter-subunit anaesthetic binding cavity and aqueous tunnel 
(a) Structure of the GLIC-GABAARα1G258Vcryst chimera showing the location of 
residues involved in anaesthetic binding (magenta, M235 & A290 (equivalent to 
M286 in β3) and the binding site for potentiating neurosteroids (shown in stick 
representation, green). Note their accommodation at the same subunit interface. (b) 
Transverse-view of an aqueous tunnel reveals that it runs close to residues 
implicated in both anaesthetic (magenta), CHS (teal) and neurosteroid (green) 
binding sites and would be accessible from the channel pore or the membrane-
exposed face of the TMD. (c) Another transverse view of the aqueous tunnel 
showing the proximity of the CHS binding site (teal) and key residues involved in 
anesthetic binding (magenta). The tunnel runs from the lipid interface at L231 in M1, 
through to the back of the ion channel at T264 (10’) in M2, near the 9’ activation 
gate, and exits into the pore at S269 (15’).  
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